# Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

> **NCT00698945** · PHASE4 · COMPLETED · sponsor: **Bp Consulting, Inc** · enrollment: 40 (estimated)

## Conditions studied

- Ocular Hypertension
- Open-Angle Glaucoma

## Interventions

- **DRUG:** Istalol and Optive
- **DRUG:** Alphagan

## Key facts

- **NCT ID:** NCT00698945
- **Lead sponsor:** Bp Consulting, Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2008-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698945, "Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00698945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*